Conditional Deletion of Cytochrome P450 Reductase in Osteoprogenitor Cells Affects Long Bone and Skull Development in Mice Recapitulating Antley-Bixler Syndrome: Role of a Redox Enzyme in Development

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Panda, Satya P ^a   Guntur, Anyonya R ^a,b   Polusani, Srikanth R ^a   Fajardo, Roberto J ^a   Gakunga, Peter T ^a   Roman, Linda J ^a   Masters, Bettie Sue ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 REDUCTASE; FIBROBLAST GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTLEY BIXLER SYNDROME; ARTICLE; BONE DEVELOPMENT; BONE MALFORMATION; BONE MASS; CONTROLLED STUDY; CRANIOFACIAL MALFORMATION; DOWN REGULATION; ENZYME METABOLISM; GENE DELETION; LONG BONE; MALE; MALOCCLUSION; MOUSE; NONHUMAN; OSTEOPROGENITOR CELL; SIGNAL TRANSDUCTION; SKULL; TIBIA; UPREGULATION;

ABNORMALITIES, MULTIPLE; ANIMALS; ANTLEY-BIXLER SYNDROME PHENOTYPE; BONE DEVELOPMENT; DOWN-REGULATION; FEMALE; FIBROBLAST GROWTH FACTORS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; SEQUENCE DELETION; SIGNAL TRANSDUCTION; SKULL; STEM CELLS; TIBIA; UP-REGULATION;

EID: 84884566129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075638     Document Type: Article

References (55)

1. Masters BS, Marohnic CC, (2006) Cytochromes P450--a family of proteins and scientists-understanding their relationships. Drug Metab Rev 38: 209-225. doi:10.1080/03602530600570065. PubMed: 16684658.
2. Otto DM, Henderson CJ, Carrie D, Davey M, Gundersen TE, et al. (2003) Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic Acid homeostasis. Mol Cell Biol 23: 6103-6116. doi:10.1128/MCB.23.17.6103-6116.2003. PubMed: 12917333.
3. Ribes V, Otto DM, Dickmann L, Schmidt K, Schuhbaur B, et al. (2007) Rescue of cytochrome P450 oxidoreductase (Por) mouse mutants reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis. Dev Biol 303: 66-81. doi:10.1016/j.ydbio.2006.10.032. PubMed: 17126317.
4. Horvat S, McWhir J, Rozman D, (2011) Defects in cholesterol synthesis genes in mouse and in humans: lessons for drug development and safer treatments. Drug Metab Rev 43: 69-90. doi:10.3109/03602532.2010.540580. PubMed: 21247357.
5. Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW, (2003) De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem 278: 38084-38093. doi:10.1074/jbc.M307028200. PubMed: 12867411.
6. Auchus RJ, (2001) The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 30: 101-119, vii doi:10.1016/S0889-8529(08)70021-5. PubMed: 11344930.
7. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, et al. (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15: 342-355. doi:10.1210/er.15.3.342. PubMed: 8076586.
8. Alam J, (2002) Heme oxygenase-1: past, present, and future. Antioxid Redox Signal 4: 559-562. doi:10.1089/15230860260220049. PubMed: 12230866.
9. Schacter BA, Nelson EB, Marver HS, Masters BS, (1972) Immunochemical evidence for an association of heme oxygenase with the microsomal electron transport system. J Biol Chem 247: 3601-3607. PubMed: 4113125.
10. Antley R, Bixler D, (1975) Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 11: 397-401. PubMed: 1227559.
11. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, et al. (2004) Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36: 228-230. doi:10.1038/ng1300. PubMed: 14758361.
12. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, et al. (2005) Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76: 729-749. doi:10.1086/429417. PubMed: 15793702.
13. Shen AL, O'Leary KA, Kasper CB, (2002) Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 277: 6536-6541. doi:10.1074/jbc.M111408200. PubMed: 11742006.
14. Wu L, Gu J, Weng Y, Kluetzman K, Swiatek P, et al. (2003) Conditional knockout of the mouse NADPH-cytochrome p450 reductase gene. Genesis 36: 177-181. doi:10.1002/gene.10214. PubMed: 12929087.
15. Wu L, Gu J, Cui H, Zhang QY, Behr M, et al. (2005) Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 312: 35-43. PubMed: 15328377.
16. Weng Y, Fang C, Turesky RJ, Behr M, Kaminsky LS, et al. (2007) Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. Cancer Res 67: 7825-7832. doi:10.1158/0008-5472.CAN-07-1006. PubMed: 17699788.
17. Fang C, Gu J, Xie F, Behr M, Yang W, et al. (2008) Deletion of the NADPH-cytochrome P450 reductase gene in cardiomyocytes does not protect mice against doxorubicin-mediated acute cardiac toxicity. Drug Metab Dispos 36: 1722-1728. doi:10.1124/dmd.108.021881. PubMed: 18463197.
18. Zhang QY, Fang C, Zhang J, Dunbar D, Kaminsky L, et al. (2009) An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine. Drug Metab Dispos 37: 651-657. doi:10.1124/dmd.108.025429. PubMed: 19056912.
19. Fang C, Bolivar VJ, Gu J, Yang W, Zeitlin SO, et al. (2012) Neurobehavioral abnormalities in a brain-specific NADPH-cytochrome P450 reductase knockout mouse model. Neuroscience 218: 170-180. doi:10.1016/j.neuroscience.2012.05.027. PubMed: 22626646.
20. Schmidt K, Hughes C, Chudek JA, Goodyear SR, Aspden RM, et al. (2009) Cholesterol metabolism: the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limb. Mol Cell Biol 29: 2716-2729. doi:10.1128/MCB.01638-08. PubMed: 19273610.
21. Yu K, Xu J, Liu Z, Sosic D, Shao J, et al. (2003) Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 130: 3063-3074. doi:10.1242/dev.00491. PubMed: 12756187.
22. Day TF, Guo X, Garrett-Beal L, Yang Y, (2005) Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8: 739-750. doi:10.1016/j.devcel.2005.03.016. PubMed: 15866164.
23. Tu X, Joeng KS, Nakayama KI, Nakayama K, Rajagopal J, et al. (2007) Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell 12: 113-127. doi:10.1016/j.devcel.2006.11.003. PubMed: 17199045.
24. Kolpakova-Hart E, McBratney-Owen B, Hou B, Fukai N, Nicolae C, et al. (2008) Growth of cranial synchondroses and sutures requires polycystin-1. Dev Biol 321: 407-419. doi:10.1016/j.ydbio.2008.07.005. PubMed: 18652813.
25. Guntur AR, Reinhold MI, Cuellar J, Naski MC, (2011) Conditional ablation of Pten in osteoprogenitors stimulates FGF signaling. Development 138: 1433-1444. doi:10.1242/dev.058016. PubMed: 21385768.
26. Seo HS, Serra R, (2007) Deletion of Tgfbr2 in Prx1-cre expressing mesenchyme results in defects in development of the long bones and joints. Dev Biol 310: 304-316. doi:10.1016/j.ydbio.2007.07.040. PubMed: 17822689.
27. Melville H, Wang Y, Taub PJ, Jabs EW, (2010) Genetic basis of potential therapeutic strategies for craniosynostosis. Am J Med Genet A 152A: 3007-3015. doi:10.1002/ajmg.a.33703. PubMed: 21082653.
28. Yeh LC, Adamo ML, Kitten AM, Olson MS, Lee JC, (1996) Osteogenic protein-1-mediated insulin-like growth factor gene expression in primary cultures of rat osteoblastic cells. Endocrinology 137: 1921-1931. doi:10.1210/en.137.5.1921. PubMed: 8612532.
29. McLeod MJ, (1980) Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. Teratology 22: 299-301. doi:10.1002/tera.1420220306. PubMed: 6165088.
30. Lecanda F, Warlow PM, Sheikh S, Furlan F, Steinberg TH, et al. (2000) Connexin 43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol 151: 931-944. doi:10.1083/jcb.151.4.931. PubMed: 11076975.
31. Keber R, Motaln H, Wagner KD, Debeljak N, Rassoulzadegan M, et al. (2011) Mouse knockout of the cholesterogenic cytochrome P450 lanosterol 14alpha-demethylase (Cyp51) resembles Antley-Bixler syndrome. J Biol Chem 286: 29086-29097. doi:10.1074/jbc.M111.253245. PubMed: 21705796.
32. Polusani SR, Kar R, Riquelme MA, Masters BS, Panda SP, (2011) Regulation of gap junction function and Connexin 43 expression by cytochrome P450 oxidoreductase (CYPOR). Biochem Biophys Res Commun 411: 490-495. doi:10.1016/j.bbrc.2011.06.132. PubMed: 21726529.
33. Liu Z, Lavine KJ, Hung IH, Ornitz DM, (2007) FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev Biol 302: 80-91. doi:10.1016/j.ydbio.2006.08.071. PubMed: 17014841.
34. Aguilar A, Wu S, De Luca F, (2009) P450 oxidoreductase expressed in rat chondrocytes modulates chondrogenesis via cholesterol- and Indian Hedgehog-dependent mechanisms. Endocrinology 150: 2732-2739. doi:10.1210/en.2009-0043. PubMed: 19264869.
35. Tsuchiya Y, Sueishi K, Yatabe K, Yamaguchi H, (2004) A case of Antley-Bixler syndrome with severe skeletal Cl. III malocclusion. Bull Tokyo Dent. Coll 45: 87-93.
36. Opperman LA, Gakunga PT, Carlson DS, (2005) Genetic Factors Influencing Morphogenesis and Growth of Sutures and Synchondroses in the Craniofacial Complex. Semin Orthod 11: 199-208. doi:10.1053/j.sodo.2005.07.004.
37. Nagata M, Nuckolls GH, Wang X, Shum L, Seki Y, et al. (2011) The primary site of the acrocephalic feature in Apert Syndrome is a dwarf cranial base with accelerated chondrocytic differentiation due to aberrant activation of the FGFR2 signaling. Bone 48: 847-856. doi:10.1016/j.bone.2010.11.014. PubMed: 21129456.
38. Laurita J, Koyama E, Chin B, Taylor JA, Lakin GE, et al. (2011) The Muenke syndrome mutation (FgfR3P244R) causes cranial base shortening associated with growth plate dysfunction and premature perichondrial ossification in murine basicranial synchondroses. Dev Dyn 240: 2584-2596. doi:10.1002/dvdy.22752. PubMed: 22016144.
39. Twigg SRF, Healy C, Babbs C, Sharpe JA, Wood WG, et al. (2009) Skeletal analysis of the Fgfr3P244R mouse, a genetic model for the Muenke craniosynostosis syndrome. Dev Dynam 238: 331-342. doi:10.1002/dvdy.21790.
40. Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM, et al. (2002) The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development 129: 3783-3793. PubMed: 12135917.
41. Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P, (2004) A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci U S A 101: 12555-12560. doi:10.1073/pnas.0405031101. PubMed: 15316116.
42. Karsenty G, (2008) Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet 9: 183-196. doi:10.1146/annurev.genom.9.081307.164437. PubMed: 18767962.
43. Long F, (2012) Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 13: 27-38. PubMed: 22189423.
44. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, et al. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764. doi:10.1016/S0092-8674(00)80258-5. PubMed: 9182763.
45. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, et al. (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108: 17-29. doi:10.1016/S0092-8674(01)00622-5. PubMed: 11792318.
46. Sinha KM, Zhou X, (2013) Genetic and molecular control of osterix in skeletal formation. J Cell Biochem 114: 975-984. doi:10.1002/jcb.24439. PubMed: 23225263.
47. Tou L, Quibria N, Alexander JM, (2001) Regulation of human cbfa1 gene transcription in osteoblasts by selective estrogen receptor modulators (SERMs). Mol Cell Endocrinol 183: 71-79. doi:10.1016/S0303-7207(01)00594-9. PubMed: 11604227.
48. Dailey L, Ambrosetti D, Mansukhani A, Basilico C, (2005) Mechanisms underlying differential responses to FGF signaling. Cytokine & Growth Factor Reviews 16: 233-247.
49. Ornitz DM, Marie PJ, (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16: 1446-1465. doi:10.1101/gad.990702. PubMed: 12080084.
50. Makarenkova H, Patel K, (1999) Gap junction signalling mediated through connexin-43 is required for chick limb development. Dev Biol 207: 380-392. doi:10.1006/dbio.1998.9171. PubMed: 10068470.
51. Dobrowolski R, Hertig G, Lechner H, Wörsdörfer P, Wulf V, et al. (2009) Loss of connexin 43-mediated gap junctional coupling in the mesenchyme of limb buds leads to altered expression of morphogens in mice. Hum Mol Genet 18: 2899-2911. doi:10.1093/hmg/ddp227. PubMed: 19439426.
52. Niger C, Buo AM, Hebert C, Duggan BT, Williams MS, et al. (2012) ERK acts in parallel to PKCδ to mediate the connexin43-dependent potentiation of Runx2 activity by FGF2 in MC3T3 osteoblasts. Am J Physiol Cell Physiol 302: C1035-C1044. doi:10.1152/ajpcell.00262pp. 2011. PubMed: 22277757.
53. Lee CH, Huang YL, Liao JF, Chiou WF, (2011) Ugonin K promotes osteoblastic differentiation and mineralization by activation of p38 MAPK- and ERK-mediated expression of Runx2 and osterix. Eur J Pharmacol 668: 383-389. doi:10.1016/j.ejphar.2011.06.059. PubMed: 21806985.
54. Stavridis MP, Collins BJ, Storey KG, (2010) Retinoic acid orchestrates fibroblast growth factor signalling to drive embryonic stem cell differentiation. Development 137: 881-890. doi:10.1242/dev.043117. PubMed: 20179094.
55. Takahashi H, Nakagawa S, (1997) Effects of estrogen on cell growth and fibroblast growth factor receptor induction in MtT/Se cells. Endocr Res 23: 95-104. doi:10.1080/07435809709031845. PubMed: 9187541.